Literature DB >> 29411055

Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and mitochondrial dysfunctions in rat model of Parkinson's disease.

Suresh Palle1, Prasad Neerati2.   

Abstract

The objective of the present study was to evaluate the protective effect of resveratrol nanoparticles (NRSV) against rotenone-induced neurodegeneration in rats. NRSV were prepared by temperature-controlled antisolvent precipitation method and characterized for its particle size, shape, and dissolution properties. Moreover, NRSV effects compared with the free resveratrol (RSV). Animals were divided into four groups: (I) control, (II) rotenone (2 mg/kg s.c.), (III) RSV (40 mg/kg, p.o.) + rotenone, and (IV) NRSV (40 mg/kg, p.o.) + rotenone. Animals received treatments 30 min before rotenone administration for a period of 35 days. Behavioral quantifications were done using rota rod test and rearing behavior after 24 h of last dose. Animals were euthanized, and mid brains were isolated for the estimation of tricarboxylic acid cycle enzymes, oxidative measures (lipid peroxidation (LPO), glutathione (GSH), and catalase), and complex-I activity. In addition, histopathological studies were also performed. Our results showed that chronic rotenone treatment causes motor deficits, decreased rearing behavior, mitochondrial dysfunction, and oxidative stress. Furthermore, histological analysis demonstrated neuronal degeneration in rotenone-treated rats. An important finding of the present study was NRSV showed comparatively better efficacy than the RSV treatment in attenuating the rotenone-induced Parkinson's like behavioral alterations, biochemical and histological changes, oxidative stress, and mitochondrial dysfunction in rats.

Entities:  

Keywords:  Nanoparticles; Parkinson’s disease; Resveratrol; Rotenone

Mesh:

Substances:

Year:  2018        PMID: 29411055     DOI: 10.1007/s00210-018-1474-8

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  43 in total

Review 1.  Levodopa in the treatment of Parkinson's disease: current controversies.

Authors:  C Warren Olanow; Yves Agid; Yoshi Mizuno; Alberto Albanese; Ubaldo Bonuccelli; U Bonucelli; Philip Damier; Justo De Yebenes; Oscar Gershanik; Mark Guttman; F Grandas; Mark Hallett; Ole Hornykiewicz; Peter Jenner; R Katzenschlager; William J Langston; Peter LeWitt; Eldad Melamed; M A Mena; P P Michel; Catherine Mytilineou; Jose A Obeso; Werner Poewe; Niall Quinn; R Raisman-Vozari; Ali H Rajput; Olivier Rascol; Christina Sampaio; Fabrizio Stocchi
Journal:  Mov Disord       Date:  2004-09       Impact factor: 10.338

Review 2.  Nanosizing--oral formulation development and biopharmaceutical evaluation.

Authors:  Filippos Kesisoglou; Santipharp Panmai; Yunhui Wu
Journal:  Adv Drug Deliv Rev       Date:  2007-05-25       Impact factor: 15.470

Review 3.  Biochemical and EPR probes for structure-function studies of iron sulfur centers of succinate dehydrogenase.

Authors:  T E King; T Ohnishi; D B Winter; J T Wu
Journal:  Adv Exp Med Biol       Date:  1976       Impact factor: 2.622

4.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

5.  The rotenone-induced rat model of Parkinson's disease: behavioral and electrophysiological findings.

Authors:  Christof von Wrangel; Kerstin Schwabe; Nadine John; Joachim K Krauss; Mesbah Alam
Journal:  Behav Brain Res       Date:  2014-11-12       Impact factor: 3.332

6.  Rotenone induced neurotoxicity in rat brain areas: a histopathological study.

Authors:  Supriya Swarnkar; Sarika Singh; Sharad Sharma; Ramesh Mathur; Ishan K Patro; Chandishwar Nath
Journal:  Neurosci Lett       Date:  2011-03-22       Impact factor: 3.046

7.  Isolation of mitochondria from ascites tumor cells permeabilized with digitonin.

Authors:  R W Moreadith; G Fiskum
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

Review 8.  Mitochondrial dysfunction in Parkinson's disease.

Authors:  Y Mizuno; H Yoshino; S Ikebe; N Hattori; T Kobayashi; S Shimoda-Matsubayashi; H Matsumine; T Kondo
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

9.  Resveratrol attenuates oxidative stress in mitochondrial Complex I deficiency: Involvement of SIRT3.

Authors:  Lise Mathieu; Alexandra Lopes Costa; Carole Le Bachelier; Abdelhamid Slama; Anne-Sophie Lebre; Robert W Taylor; Jean Bastin; Fatima Djouadi
Journal:  Free Radic Biol Med       Date:  2016-04-25       Impact factor: 7.376

10.  Cell-based in vitro blood-brain barrier model can rapidly evaluate nanoparticles' brain permeability in association with particle size and surface modification.

Authors:  Sanshiro Hanada; Kouki Fujioka; Yuriko Inoue; Fumihide Kanaya; Yoshinobu Manome; Kenji Yamamoto
Journal:  Int J Mol Sci       Date:  2014-01-24       Impact factor: 5.923

View more
  21 in total

Review 1.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

2.  Protective Effect of (-)Epigallocatechin-3-gallate on Rotenone-Induced Parkinsonism-like Symptoms in Rats.

Authors:  Hsiang-Chien Tseng; Mao-Hsien Wang; Kuo-Chi Chang; Hung-Sheng Soung; Chih-Hsiang Fang; Yi-Wen Lin; Keng-Yuan Li; Chih-Chuan Yang; Cheng-Chia Tsai
Journal:  Neurotox Res       Date:  2019-12-06       Impact factor: 3.911

Review 3.  Neuroprotective Effects of Resveratrol in In vivo and In vitro Experimental Models of Parkinson's Disease: a Systematic Review.

Authors:  Michele Goulart Dos Santos; Lucia Emanueli Schimith; Corinne André-Miral; Ana Luiza Muccillo-Baisch; Bruno Dutra Arbo; Mariana Appel Hort
Journal:  Neurotox Res       Date:  2022-01-11       Impact factor: 3.911

Review 4.  Targeting Mitochondria as a Therapeutic Approach for Parkinson's Disease.

Authors:  Maryam Abrishamdar; Maryam Sadat Jalali; Yaghoob Farbood
Journal:  Cell Mol Neurobiol       Date:  2022-08-11       Impact factor: 4.231

Review 5.  Resveratrol in Rodent Models of Parkinson's Disease: A Systematic Review of Experimental Studies.

Authors:  Cheng-Fu Su; Li Jiang; Xiao-Wen Zhang; Ashok Iyaswamy; Min Li
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

Review 6.  Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment.

Authors:  Stephanie Andrade; Maria João Ramalho; Maria do Carmo Pereira; Joana A Loureiro
Journal:  Front Pharmacol       Date:  2018-11-20       Impact factor: 5.810

7.  Resveratrol Activates Autophagy via the AKT/mTOR Signaling Pathway to Improve Cognitive Dysfunction in Rats With Chronic Cerebral Hypoperfusion.

Authors:  Nan Wang; Jinting He; Chengliang Pan; Jiaoqi Wang; Ming Ma; Xinxiu Shi; Zhongxin Xu
Journal:  Front Neurosci       Date:  2019-08-20       Impact factor: 4.677

Review 8.  Resveratrol Derivatives as Potential Treatments for Alzheimer's and Parkinson's Disease.

Authors:  Bruno Dutra Arbo; Corinne André-Miral; Raif Gregorio Nasre-Nasser; Lúcia Emanueli Schimith; Michele Goulart Santos; Dennis Costa-Silva; Ana Luiza Muccillo-Baisch; Mariana Appel Hort
Journal:  Front Aging Neurosci       Date:  2020-04-17       Impact factor: 5.750

9.  Anti-Apoptotic and Anti-Inflammatory Role of Trans ε-Viniferin in a Neuron-Glia Co-Culture Cellular Model of Parkinson's Disease.

Authors:  Domenico Sergi; Alex Gélinas; Jimmy Beaulieu; Justine Renaud; Emilie Tardif-Pellerin; Jérôme Guillard; Maria-Grazia Martinoli
Journal:  Foods       Date:  2021-03-11

10.  Neuroprotective Effects of Pomegranate Juice against Parkinson's Disease and Presence of Ellagitannins-Derived Metabolite-Urolithin A-In the Brain.

Authors:  Małgorzata Kujawska; Michael Jourdes; Monika Kurpik; Michał Szulc; Hanna Szaefer; Piotr Chmielarz; Grzegorz Kreiner; Violetta Krajka-Kuźniak; Przemyslaw Łukasz Mikołajczak; Pierre-Louis Teissedre; Jadwiga Jodynis-Liebert
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.